Whitepapers

In this application note, we pair Simple Plex Assays on Ella with Cygnus 3G CHO antibodies for superior sensitivity and data reproducibility throughout bioproduction.

This white paper demonstrates a vendor’s perspective on recent trends in regulations and the potential future direction for the industry.

Bring vaccines and therapies to market faster through earlier production control planning, standard pre-structured automation designs, and advanced technology. 

This paper answers a major concern of manufacturers: Do x-rays affect the quality and efficacy of a drug during product inspection?

In this application note, we pair Simple Plex Assays on Ella with Cygnus 3G CHO antibodies for superior sensitivity and data reproducibility throughout bioproduction.

This whitepaper will cover the challenges in developing a modified release dosage form and share key strategies & case studies on how to accelerate their development.

This white paper shows how UV/VIS Excellence spectrophotometers can increase speed and accuracy when characterizing vaccine candidates and their components.

Learn practical tips to improve cybersecurity in your facility to protect workers, processes, and ultimately the patients that depend on your product.

In this application note, we pair Simple Plex Assays on Ella with Cygnus 3G CHO antibodies for superior sensitivity and data reproducibility throughout bioproduction.

In this ondemand webinar we discuss how drug developers can maximize capacity, capabilities, and expertise for pandemic response and how pharma and biotech innovators are working together to combat COVID-19.

Learn more about speed-to-market, a critical aspect of developing new pharmaceutical products, and the significant interest on the science of scale for spray drying.

Download this buyer's guide to learn more about recent pharmaceutical manufacturing trends and discover the tools and insights you need to help find the right QMS.

Coupling a headspace sampling technique with a HRAM GC-MS system provides quick assessments and quantifies potentially dangerous, untargeted volatile extractables

This white paper will give readers a vendor’s perspective on recent trends in regulations and the potential future direction for the industry - being referred to as “Pharma 4.0”.

This whitepaper will cover five areas for consideration by oncology drug developers & the potential solutions in development, manufacturing & supply that are emerging.